Introduction
============

Nephronophthisis (NPH) is a rare autosomal recessive disease associated with chronic kidney disease and renal failure as well as multiple extrarenal manifestations. Currently, 17 genes have been identified that can cause NPH manifestations; however, these known genes account for approximately half of the patients, presenting with NPH. As most gene products mutated in NPH localize to the cilium, NPH is considered a ciliopathy, that is, a syndrome caused by defective ciliary functions. Most nephrocystins appear to form large protein networks at the basal body and the transition zone to execute ciliary functions.^[@bib1],\ [@bib2]^ However, NPH type VII represents an exception: GLIS2/NPHP7 is a zinc-finger protein that recognizes the DNA motif (G/C)TGGGGGGT(A/C), acting as a transcriptional repressor or co-activator.^[@bib3]^ GLIS2/NPHP7 knockout mice suggest that this protein suppresses genes associated with mesenchymal characteristics, maintaining an epithelial phenotype.^[@bib4]^ GLIS2/NPHP7 inhibits Snai1 and Wnt4 by binding *cis*-acting regulatory sequences, thereby antagonizing hedgehog and Wnt signaling.^[@bib5]^ In the absence of GLIS2/NPHP7, genes that facilitate an epithelial-to-mesenchymal transition are increasingly expressed, promoting fibrosis and renal failure.^[@bib4],\ [@bib5],\ [@bib6]^ Recently, a GLIS2/NPHP7 c.523T\>C mutation in both the alleles of Glis2, resulting in a C175R substitution at the beginning of the first zinc-finger domain of GLIS2/NPHP7, was identified in a patient with end-stage renal disease,^[@bib7]^ suggesting that this point mutation was responsible for the NPH manifestation. As the differentiation between disease-relevant point mutations and irrelevant amino-acid substitutions represents a major challenge in determining the significance of novel human mutations, we decided to study the GLIS2/NPHP7^C175R^ mutant in more detail.

Materials and methods
=====================

Sequence reference
------------------

More information about the C175R mutation can be found at <http://www.ensembl.org>, SNP ID: rs587777353. The reference sequences for human GLIS2/NPHP7^C175R^ are NG_016391.1 (gene ID), NM_032575.2 (mRNA), NP_115964.2 (protein) at <http://www.ncbi.nlm.nih.gov>.

Cell culture and transfections
------------------------------

Human embryonic kidney (HEK 293T) cells were cultured in Dulbecco\'s modified Eagle medium supplemented with 10% fetal bovine serum. The cells were transfected with using calcium phosphate method.

Co-precipitation and western blotting
-------------------------------------

Transfected HEK 293T cells were washed with PBS, and lysed in lysis buffer (20 m[m]{.smallcaps} Tris, pH 7.5, 1% Triton X-100, 50 m[m]{.smallcaps} NaCl, 50 m[m]{.smallcaps} NaF, 15 m[m]{.smallcaps} Na~4~P~2~O~7~, 0.1 m[m]{.smallcaps} EDTA) supplemented with protease inhibitors. After sonication and centrifugation, the lysates were incubated with Flag M2 sepharose beads (Sigma, Taufkirchen, Germany), or V5 antibody-coated sepharose beads (Abcam, Cambridge, UK), washed with lysis buffer. The proteins were eluted in 2x Laemmeli buffer supplemented with DTT. The bound proteins were resolved by SDS-PAGE, and the interactions were visualized by western blotting using the appropriate antibodies.

Zebrafish embryo manipulation
-----------------------------

Transgenic *wt1b:GFP* zebrafish strain was maintained and raised as described.^[@bib8]^ Fertilized eggs were microinjected at the one-to-two-cell stage with 4 nl of injection solution containing morpholino oligonucleotides (MOs; Gene Tools LLC, Philomath, OR, USA) and/ or RNA diluted in 200 m[m]{.smallcaps} KCl, 0.1% phenol red (Sigma-Aldrich Corporation, St Louis, MO, USA) and 10 m[m]{.smallcaps} HEPES. The *nphp7.2* splice-blocking MO (*znphp7.1* SP MO; 5′-TATAATATCCACAGTCTGACCTGGC-3′) has been previously described.^[@bib9]^ All MOs were co-injected with 0.4 pmol of zebrafish *p53* MO (5′-GCGCCATTGCTTTGCAAGAATTG-3′, Gene Tools) to reduce the unspecific effects of the reagents.^[@bib10]^ Standard control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′ Gene Tools) was used in the control experiments. The cloning and the synthesis of *nphp7.2* RNA for injection have been previously described.^[@bib9]^ The *nphp7.2-pCS2+* construct was used in a QuickChange assay (Qiagen, Hilden, Germany) to generate the *nphp7.2 C175R* mutant construct. Analysis and image acquisition of normal and cystic pronephri were performed under a Leica MZ16 stereo microscope equipped with a Leica DFC450 C camera (Leica, Solms, Germany). Adjustments of image brightness and contrast were performed in Photoshop. The Statistical analysis was carried out in R (R Core Team, Foundation for Statistical Computing, Vienna, Austria; <http://www.R-project.org/>), using the results from Woolf\'s test and Cochran--Mantel--Haensel test on 2x2x5 contingency tables.

Results
=======

The comparison of wild-type and mutant GLIS2/NPHP7 using the SMART analysis tool (<http://smart.embl-heidelberg.de/>) revealed that the C175R point mutation abolished the prediction of the first zinc-finger ([Figure 1a](#fig1){ref-type="fig"}). Several GLIS2/NPHP7-binding proteins have been identified that appear to affect the function and/or localization of this transcriptional repressor. Importantly, binding of *β*-catenin and canonical Wnt signaling appears to involve the first zinc-finger, the site of the C175R mutation, while binding of CtBP1, a transcriptional co-repressor involved in HDAC3-mediated gene silencing complex seem to occur within the C-terminal domain of GLIS2/NPHP7. To determine whether the C175R mutation disrupts the interaction with important binding partners, we tested the interaction with CtBP1, HDAC3 and *β*-catenin. However, we observed no differences between wild-type and mutant GLIS2/NPHP7 with these three proteins ([Figure 1b and c](#fig1){ref-type="fig"}), suggesting that the C175R mutation does not compromise the overall conformation of GLIS2/NPHP7, or abrogate the interaction with defined binding partners.

GLIS2/NPHP7 is a labile protein targeted for proteasome-dependent degradation.^[@bib11]^ The ELM analysis tool ([www.elm.eu.org](http://www.elm.eu.org)) predicted a novel CDH1/CDC20-binding site ([Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}). Both proteins are subunits of the anaphase-promoting complex, a large E3 ligase that targets several cell cycle components for proteasomal degradation, suggesting that the p.C175R may increase the turnover of GLIS2/NPHP7. Indeed, co-immunoprecipitation assays confirmed that GLIS2/NPHP7^C175R^ interacted with CDH1, whereas no interaction was detectable for CDC20 ([Supplementary Figures 1b and 1d](#sup1){ref-type="supplementary-material"}). In addition, GLIS2/NPHP7^C175R^ interacted stronger with CDH1 than wild-type GLIS2/NPHP7 ([Supplementary Figure 1c](#sup1){ref-type="supplementary-material"}). We therefore examined next whether the C175R mutation destabilizes the GLIS2/NPHP7 gene product, thereby compromising the function of this transcriptional repressor. Although steady-state levels of mutant GLIS/NPHP7 were not apparently altered in comparison with wild-type protein ([Figure 2a](#fig2){ref-type="fig"}), we compared the half-life of wild-type and mutated GLIS2/NPHP7 after inhibition of protein synthesis by cycloheximide to further exclude a change in stability. Both proteins showed a comparable decline within a 9-h chase period, suggesting that the C175R does not significantly affect protein stability ([Supplementary Figure 2a](#sup1){ref-type="supplementary-material"}). Furthermore, MG132 increased the levels of both proteins, suggesting that the recognition of GLIS2/NPHP7 and proteasomal degradation is not affected by the C175R mutation. As the Bardet--Biedl syndrome (BBS) gene product BBS11/TRIM32 facilitates the accumulation of ubiquitinated GLIS2/NPHP7,^[@bib11]^ and interacts with wild-type and mutant GLIS2/NPHP7 ([Figure 2a](#fig2){ref-type="fig"}), we tested whether BBS11/TRIM32 differentially affects the ubiquitination state of wild-type or mutant GLIS2/NPHP7. However, both the mutant and the wild-type proteins were extensively ubiquitinated in the presence of BBS11/TRIM32, suggesting that the ubiquitination of GLIS2/NPHP7 is not altered by the C175R mutation ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}).

Although the properties of GLIS2/NPHP7 as transcriptional repressor are well established (reviewed in the study by Lichti-Kaiser *et al.*^[@bib12]^), GLIS2/NPHP7 does not contain a conventional nuclear localization signal. Instead, nuclear import depends upon an intact third zing-finger; C-terminal and N-terminal deletions localized the nuclear targeting motif to a region between the amino acids 246--256 outside of the C175R mutation.^[@bib3]^ Examining the localization of the GLIS2/NPHP7, we observed that fluorescently labeled wild-type GLIS2/NPHP7 localized almost exclusively to the nucleus ([Figure 2b](#fig2){ref-type="fig"}). However, the identically tagged GLIS2/NPHP7^C175R^ mutant localized predominantly to the cytoplasm outside of the nucleus. This surprising result was confirmed by cell compartment fractionation. Although wild-type GLIS2/NPHP7 was present in both the cytoplasmic and the nuclear compartment, the mutant protein was predominantly present in the cytosolic fraction ([Figure 2c](#fig2){ref-type="fig"}), suggesting that the cysteine at position 175 has an important role in the trafficking of GLIS2/NPHP7 to the nucleus.

We tested next whether the mutation affects the transcriptional activity of GLIS2/NPHP7. GLIS2/NPHP7 has been implicated in multiple transcriptional networks. Although GLIS2/NPHP7 represses Wnt presumably through interaction with *β*-catenin, GLIS2/NPHP7 also has a role as transcriptional activator, and stimulates the mouse insulin-2 promoter (mIns2).^[@bib3]^ Consistent with the predominant cytosolic localization of the GLIS2/NPHP7^C175R^, the mutant protein failed to activate a mIns2 luciferase construct ([Figure 3b](#fig3){ref-type="fig"}). As small amounts of GLIS2/NPHP7^C175R^ were present in the nucleus ([Figure 2b](#fig2){ref-type="fig"}), we addressed the possibility that the mutation, located within the first zinc-finger additionally affects the transcriptional function of GLIS2/NPHP7. We utilized a consensus nuclear localization sequence (NLS), fused to the N terminus of GLIS2/NPHP7, to force the protein into the nucleus ([Figure 3a](#fig3){ref-type="fig"}). However, despite re-establishing the nuclear localization, the NLS GLIS2/NPHP7^C175R^ mutant failed to activate the mIns2 promoter, implying that the C175R point mutation also affects DNA recognition and/or binding ([Figure 3b](#fig3){ref-type="fig"}).

To further confirm the disease relevance of GLIS2/NPHP7^C175R^, we utilized the zebrafish pronephros model. Knockdown of the zebrafish isoform *nphp7.2* results in cyst formation, which can be rescued by zebrafish *nphp7.2* mRNA.^[@bib9]^ We generated the corresponding *nphp7.2* mutation, and performed the rescue experiments in parallel with wild-type *nphp7.2* mRNA ([Figure 3c, d and e](#fig3){ref-type="fig"}). Although wild-type mRNA ameliorated the phenotype and reduced cyst formation, there was no reduction but even a slight increase in zebrafish embryos microinjected with the mutant mRNA ([Figure 3e](#fig3){ref-type="fig"}).

Discussion
==========

One of the major obstacles in characterizing the *in vivo* functions of GLIS2/NPHP7 has been the failure to detect native GLIS2/NPHP7 protein. Although *GLIS2/NPHP7* mRNA is ubiquitously expressed, GLIS2/NPHP7 protein levels appear to be tightly regulated evading detection by western blot analysis.^[@bib5]^ Thus, GLIS2/NPHP7 has been almost exclusively characterized in heterologous expression systems. Given the lack of NPH-typical extrarenal manifestations in the patient with the GLIS2/NPHP7^C175R^ mutation, we hypothesized that studying this point mutation might reveal additional insights into the function and structural requirements of GLIS2/NPHP7. Our findings confirm the pathogenicity of the GLIS2/NPHP7^C175R^ point mutation, and reveal that the point mutation surprisingly alters both the nuclear import as well as the transcriptional activity of GLIS2/NPHP7. These changes occur despite the preserved interactions with *β*-catenin, CtBP1, BBS11/TRIM32 and HDAC3, suggesting that the overall architecture of GLIS2/NPHP7 is not affected by this mutation. Indeed, although the interaction between Glis2 and *β*-catenin has been mapped to the first zinc-finger, the mutation of the conserved cysteine at position 175 required to form a zinc-finger did not abolish the interaction with *β*-catenin; in fact, the interaction appeared slightly enhanced due to increased protein levels of the Glis2 C175R mutation. As most NPH gene products localize to the cilium, NPH is generally considered a ciliopathy. However, our findings provide further support for the nuclear function of GLIS2/NPHP7, and suggest that defective transcriptional functions are responsible for the NPH manifestations in patients with GLIS2/NPHP7 mutations.
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[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![The GLIS2/NPHP7^C175R^ mutation does not disrupt the interaction with known interacting proteins. (**a**) The GLIS2/NPHP7^C175R^ mutation abolishes the prediction of the first zinc-finger (SMART analysis tool). (**b**) Interaction of V5-tagged wild-type GLIS2/NPHP7 (V5.NPHP7.WT) with Flag-tagged CtBP1, HDAC3 and *β*-catenin. CD2AP was used as a negative control. HC indicates heavy chain of antibodies. The additional bands in lanes 2 and 4 are likely non-specific background due cross-reactivity of the anti-Flag antibody and slightly higher protein concentrations in these lanes. (**c**) Interaction of V5-tagged mutant GLIS2/NPHP7^C175R^ (V5.NPHP7^C175R^) with Flag-tagged CtBP1, HDAC3 and *β*-catenin. CD2AP was used as a negative control. There was no detectable difference regarding the interaction of these three candidate proteins. IP, immunopricipitation; WB, western blot.](ejhg2015199f1){#fig1}

![The C175R substitution affects the nuclear localization of the transcriptional regulator GLIS2/NPHP7. (**a**) Steady-state levels of V5-tagged wild-type GLIS2/NPHP7 (V5.GLIS2.WT) and GLIS2/NPHP7^C175R^. Expression levels of mutant GLIS2/NPHP7^C175R^ are not decreased, but are rather increased. (**b**) The interaction of GLIS2/NPHP7^C175R^ with BBS11/ TRIM32 is preserved (V5.NPHP7 species, V5-tagged GLIS2/NPHP7 species; HC, immunoglobulin heavy chain). (**c**) GLIS2/NPHP7 tagged with YFP localizes primarily to the nucleus. In contrast, YFP-tagged GLIS2/NPHP7^C175R^ is predominantly retained in the cytoplasm, and only a small fraction is detectable in the nucleus. (**d**) Nuclear fractionation in combination with western blot analysis confirms that a significant portion of wild-type (WT) GLIS/NPHP7 resides in the nuclear fraction (SNF), whereas most of the GLIS2/NPHP7^C175R^ mutant is found in the cytosolic fraction (SCF). IP, immunopricipitation; SNF, soluble nuclear fraction; SCF, soluble cytosolic fraction; WB, western blot.](ejhg2015199f2){#fig2}

![Forced nuclear localization does not re-establish the transcriptional activity of GLIS2/NPHP7^C175R^. (**a**) A consensus nuclear localization sequence (NLS) fused to the amino terminus re-establishes the nuclear localization of GLIS2/NPHP7^C175R^. (**b**) Although wild-type GLIS2/NPHP7 activates the mouse insulin-2 promoter, both GLIS2/NPHP7^C175R^ and GLIS2/NPHP7^C175R^ fused with a NLS fail to activate this promoter luciferase construct. (**c**) Wild-type-like pronephric morphology of 48 -h-old zebrafish embryo injected with control morpholino oligonucleotide (MO). In these experiments, the *wt1b:GFP* transgenic zebrafish line that labels the glomeruli and the proximal tubules was used. (**d**) In contrast, *nphp7.2* MO injected embryos develop pronephric cysts, evident in the dilation of the glomeruli and the proximal tubules (outlined in white). (**e**) Knockdown of zebrafish *nphp7.2* with splice-blocking MOs (0.1 m[m]{.smallcaps})^[@bib9]^ results in pronephric cysts. Co-expression of zebrafish *nphp7.2* mRNA (300 ng/μl; WT RNA) rescues the phenotype and reduces cyst formation. In contrast, the corresponding *nphp7.2* mutation (C175R RNA; 300 ng/μl) fails to rescue the phenotype, and instead slightly increases cyst formation. Neither wild-type nor mutant *nphp7.2 m*RNA displays a significant phenotype, if co-expressed with a control MO. The black bars represent the average percentages of cyst formation from five independent experiments (*N*). The numbers within the bars represent the total number of embryos analyzed (*n*). To calculate the depicted *P*-values, the Cochran--Mantel--Haenszel test was used. For complete statistical analysis, see [Supplementary Materials](#sup1){ref-type="supplementary-material"}. Scale bar, 100 μm in **c** and **d**.](ejhg2015199f3){#fig3}
